London, 30 January 2015 – TechNavio has announced the publication of a new market research report on the Active Pharmaceutical Ingredients (API) Market in US, which is expected to grow at a CAGR of 7.01 percent from 2014-2019.
About the Report
According to the latest report by TechNavio, the key vendors in the API market in the US are expected to focus more on the development and commercialization of high-potency API in the coming years. Demand for these products is substantial and is expected to be strong during the forecast period because of an increase in the application of targeted therapy for treatment of diseases.
“The increasing use of active pharmaceutical ingredients in drugs for oncology will drive the growth of API Market in US,” says Faisal Ghaus, Vice President of TechNavio.
Furthermore, the report emphasizes an increase in the number of collaborations and mergers. The growth potential of the market has attracted a number of new entrants and is posing a competitive threat to existing SMEs. This has led to an increasing number of joint ventures between these vendors in order to maintain market position.
“Vendors are showing interest in technological collaborations and R&D alliances so as to remain competitive,” says Ghaus.
Key Information Covered in the Report:
Market segmentation, size and forecast through 2019
Market Growth Drivers:
- Increased Preference for Generic Drugs
- For a full detailed list, view our report.
Market Challenges:
- Decrease in R&D Spending
- For a full detailed list, view our report.
Market Trends:
- Strong Focus on High-potency API
- For a full detailed list, view our report.
Key Vendors:
- Abbott Laboratories
- Aurobindo Pharma Ltd.
- Mylan Inc.
- Teva Pharmaceutical Industries Ltd.
Other Prominent Vendors:
- Albemarle
- Aptuit
- BASF
- Biocon
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
